BURLINGTON, Mass., Nov. 03, 2023 (GLOBE NEWSWIRE) -- LeMaitre Vascular, Inc. (Nasdaq:LMAT) announced today that management will be participating in three upcoming investor conferences in November.
Jefferies London Healthcare Conference
Tuesday, November 14, 2023
London, UK
JJ Pellegrino, Chief Financial Officer, will present at 11:00 AM GMT
Stifel's 2023 Healthcare Conference
Tuesday, November 14, 2023
Lotte NY Palace Hotel, New York City
David Roberts, President, will present at 1:50 PM ET
Piper Sandler 35th Annual Healthcare Conference
Wednesday, November 29, 2023
Lotte NY Palace Hotel, New York City
David Roberts, President, will present at 2:10 PM ET
About LeMaitre
LeMaitre is a provider of devices, implants and services for the treatment of peripheral vascular disease, a condition that affects more than 200 million people worldwide. The Company develops, manufactures and markets disposable and implantable vascular devices to address the needs of its core customer, the vascular surgeon. The Company's diversified product portfolio consists of brand name devices used in arteries and veins outside of the heart. Additional information can be found at www.lemaitre.com.
| Last Trade: | US$82.61 |
| Daily Change: | 0.26 0.32 |
| Daily Volume: | 102,153 |
| Market Cap: | US$1.870B |
May 05, 2025 May 01, 2025 April 01, 2025 February 27, 2025 | |
Terns Pharmaceuticals is a clinical-stage biopharmaceutical company developing a portfolio of small-molecule product candidates to address serious diseases, including oncology and obesity. Terns’ pipeline contains three clinical stage development programs including GLP-1 receptor...
CLICK TO LEARN MORE
C4 Therapeutics is pioneering a new class of small-molecule drugs that selectively destroy disease-causing proteins via degradation using the innate machinery of the cell. This targeted protein degradation approach offers advantages over traditional drugs, including the potential to treat a wider range of diseases...
CLICK TO LEARN MORE
